Join a Study

Current Drug-Resistant Urinary Tract Infection (UTI)

  • Drug-Resistant Urinary Tract Infection (UTI)
  • Location(s): Rovia Doral (Universal Axon Site)

A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug-Resistant E. Coli

This study evaluates an investigational treatment called LBP-EC01, which uses bacteriophages (viruses that target bacteria) to treat acute UTIs caused by drug-resistant E. coli. Participants will receive either the study drug or a placebo, both alongside standard antibiotic therapy. The goal is to find a safe and more effective way to treat UTIs when traditional antibiotics may not work.

Eligibility:
• Adults with a recent history of UTIs caused by drug-resistant E. coli
• Currently experiencing an uncomplicated UTI
• Not currently taking antibiotics to treat this infection

Apply Now